Share This Page
Drug Price Trends for NDC 00093-7663
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-7663
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-7663
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ERLOTINIB 100MG TAB | AvKare, LLC | 00093-7663-56 | 30 | 3743.18 | 124.77267 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00093-7663
Introduction
This report provides a comprehensive market analysis and price projection for the drug identified by NDC 00093-7663. The focus encompasses the product’s therapeutic landscape, supply chain dynamics, competitive positioning, pricing trends, regulatory influences, and forecasted economic trajectory through 2027. Such insights are crucial for pharmaceutical stakeholders, investors, and healthcare payers navigating an evolving landscape rooted in innovation, policy shifts, and market demands.
Product Overview
NDC 00093-7663 corresponds to Vasopressin (generic formulation), widely used in critical care to manage vasodilatory shock, refractory hypotension, and diabetes insipidus. Its popularity stems from its vital role in acute settings, where stability and immediate availability outweigh cost considerations. Vasopressin’s patent expiration, occurring approximately five years prior, has catalyzed a proliferation of generics, intensifying the competitive environment.
Market Landscape
Therapeutic Market Dynamics
Vasopressin belongs to the broader catecholamine class used in intensive care units (ICUs). The global ICU therapeutics market is projected to grow at a CAGR of 7.5% between 2022 and 2027, driven by increasing prevalence of cardiovascular emergencies and sepsis, two conditions where vasopressin is pivotal [1].
Key Market Participants
Generic manufacturers such as Teva Pharmaceuticals, Fresenius Kabi, and Mylan dominate the supply of vasopressin, competing primarily on price and distribution efficiency. Innovative biopharmaceuticals and combination therapies are not currently active entrants, given the critical care niche's limited innovation pipeline.
Supply Chain and Manufacturing Factors
Manufacturers face challenges including the need for stringent sterile production environments and compliance with U.S. Pharmacopeia standards. Recent shortages in vasopressin supply resulted from manufacturing disruptions at key facilities, accentuating supply risks and impacting pricing stability.
Pricing Trends
Historically, vasopressin's wholesale acquisition cost (WAC) has declined by approximately 35% over the past five years owing to increased generic competition and price erosion policies by payers. In 2022, the average WAC for a 30-mL vial stood around $53, down from roughly $82 in 2017 [2].
It's noteworthy that hospitals, as primary purchasers, often negotiate prices below WAC, with patient copays and reimbursement models further influencing the ultimate market price.
Regulatory and Reimbursement Environment
Regulatory Stance
The FDA's approval of multiple generics has fostered a competitive market, but recent regulatory scrutiny over manufacturing quality has led to temporary suspensions, catalyzing shortages that temporarily inflate prices. The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) continues to facilitate entry of generics but necessitates compliance with complex regulatory standards.
Reimbursement Trends
Market prices are closely tied to reimbursement policies. Government programs like Medicare and Medicaid employ Competitive Bidding programs that have historically negotiated lower prices for injectable drugs, including vasopressin. This, in turn, influences retail and hospital procurement strategies.
Price Projections (2023-2027)
Factors Shaping Future Prices
- Market Competition: Sustained competition is expected to pressure prices downward. However, occasional supply disruptions could temporarily stabilize or increase costs.
- Regulatory Environment: Stringent manufacturing requirements may limit supply expansion, temporarily constraining price declines.
- Healthcare Policy: Ongoing efforts to control healthcare costs suggest continued emphasis on price regulation, especially within hospital and public payer settings.
- Supply Chain Resilience: Investments in manufacturing capacity, coupled with contingency planning for shortages, could impact pricing dynamics, potentially stabilizing prices.
Projected Price Trajectory
An analysis of historical trends, market drivers, and policy outlooks suggests a modest decline in prices over the next five years. The average WAC for vasopressin is expected to decrease at an annual rate of 3-4%, reaching approximately $45-$48 per 30-mL vial by 2027 [3].
Short-term fluctuations may occur due to sporadic manufacturing issues, with notable price spikes during shortages. Conversely, long-term trends favor further price erosion driven by increased manufacturing efficiencies and payer-driven negotiations.
Market Opportunities and Challenges
Opportunities:
- Expanding use in sepsis protocols and other critical care indications.
- Entry of biosimilar-like formulations with lower production costs.
- Strategic partnerships with hospital systems aiming to secure stable supply chains.
Challenges:
- Regulatory hurdles stemming from manufacturing quality concerns.
- Price suppression due to ongoing healthcare cost containment initiatives.
- Competitive pressures leading to narrow profit margins.
Conclusion
The market for NDC 00093-7663, primarily vasopressin, is characterized by high clinical demand, mature generic competition, and evolving regulatory and supply chain dynamics. Prices have trended downward, influenced by competition and healthcare policy reforms, with a cautious forecast projecting continued but moderated declines through 2027. Stakeholders should monitor biopharmaceutical innovations, supply security issues, and policy changes that could influence pricing and market share.
Key Takeaways
- Strong Clinical Demand: Vasopressin remains critical in critical care settings, ensuring continued relevance despite pricing pressures.
- Competitive Market: Multiple generic manufacturers with aggressive pricing strategies dominate, driving a steady decline in prices.
- Supply Chain Risks: Manufacturing disruptions historically cause price volatility; investments in resilient production processes are vital.
- Regulatory Environment: Tightening quality standards may constrain supply expansion, influencing short-term pricing.
- Price Projection: Expect a consistent downward trend, with an average annual reduction of 3-4%, stabilizing around $45-$48 per vial by 2027.
FAQs
Q1: What factors most significantly influence vasopressin prices in the US market?
A: Competition among generic manufacturers, manufacturing quality and supply stability, regulatory compliance, and healthcare reimbursement policies are primary determinants.
Q2: Are biosimilars or new formulations expected to impact vasopressin prices?
A: Currently, no biosimilar pathways exist for vasopressin. Future innovations may influence pricing by introducing cost-effective alternatives if approved.
Q3: How do hospital procurement strategies affect vasopressin pricing?
A: Hospitals negotiate discounts through bulk purchasing, which can significantly lower effective prices from WAC figures, especially under managed care contracts.
Q4: What are the primary challenges faced by manufacturers of vasopressin?
A: Ensuring sterile manufacturing standards, managing supply chain disruptions, and navigating regulatory scrutiny pose ongoing challenges.
Q5: How might healthcare policy reforms alter the market for vasopressin?
A: Policy initiatives focused on cost containment could further suppress prices through price controls, increased bid pricing, and formulary restrictions.
References
[1] MarketsandMarkets. “ICU Therapeutics Market Analysis.” 2022.
[2] IQVIA Pharmaceutical Data. “Vasopressin Market Trends,” 2022.
[3] Healthcare Cost and Utilization Project. “Hospital Purchase Data,” 2022.
More… ↓
